Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:23:13 EDT Mon 14 Oct 2024
Enter Symbol
or Name
USA
CA



Q:TVTX - TRAVERE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TVTX - Q0.116.40·18.250.117.44+1.036.31,596.026,56410,59216.46  17.49  16.1818.60  5.1216:01:28Sep 2615 min RT 2¢

Recent Trades - Last 10 of 10592
Time ETExPriceChangeVolume
16:01:28Q17.441.03260
16:01:26Q17.441.03559
16:01:09Q17.441.03144
16:01:06Q17.441.03129
16:00:57Q17.441.03244
16:00:09Q17.441.03700
16:00:09Q17.441.032,398
16:00:09Q17.441.031,920
16:00:02Q17.441.0377
16:00:02Q17.441.0373

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-26 16:01U:TVTXNews ReleaseTravere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
2024-09-12 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-10 16:01U:TVTXNews ReleaseTravere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
2024-09-05 17:34U:TVTXNews ReleaseTravere Therapeutics Announces Full FDA Approval of FILSPARI(TM) (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
2024-08-22 16:30U:TVTXNews ReleaseTravere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
2024-08-06 16:30U:TVTXNews ReleaseTravere Therapeutics to Present at Upcoming Investor Conferences
2024-08-01 16:01U:TVTXNews ReleaseTravere Therapeutics Reports Second Quarter 2024 Financial Results
2024-07-25 16:30U:TVTXNews ReleaseTravere Therapeutics to Report Second Quarter 2024 Financial Results
2024-07-08 16:30U:TVTXNews ReleaseTravere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
2024-06-11 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-15 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-09 16:31U:TVTXNews ReleaseTravere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
2024-05-08 16:30U:TVTXNews ReleaseTravere Therapeutics to Present at Upcoming Investor Conferences
2024-05-06 16:01U:TVTXNews ReleaseTravere Therapeutics Reports First Quarter 2024 Financial Results
2024-04-29 16:30U:TVTXNews ReleaseTravere Therapeutics to Report First Quarter 2024 Financial Results
2024-04-24 07:05U:TVTXNews ReleaseTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI(TM) (sparsentan) for the treatment of IgA Nephropathy
2024-04-24 03:00U:TVTXNews ReleaseCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI(TM) (sparsentan) for the treatment of IgA Nephropathy
2024-04-04 16:30U:TVTXNews ReleaseTravere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
2024-04-03 16:30U:TVTXNews ReleaseTravere Therapeutics to Present Abstracts on FILSPARI(TM) (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
2024-03-13 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)